Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31510034 | 1.00 | MEN1 (0.48) | MEN1KMT2ATDP1ALDH1A1KDM4E | |
| SCHEMBL23706240 | 0.84 | MEN1 (0.47) | MEN1KMT2ATDP1ALDH1A1KDM4E | |
| SCHEMBL30041905 | 0.84 | MEN1 (0.47) | MEN1KMT2ATDP1ALDH1A1KDM4E | |
| SCHEMBL1169501 | 0.78 | KMT2A (0.56) | MEN1KMT2ATDP1ALDH1A1KDM4E | |
| SCHEMBL13018952 | 0.78 | ATM (0.65) | MEN1KMT2ATDP1ALDH1A1KDM4E | |
| SCHEMBL1459847 | 0.75 | HPGD (0.58) | MEN1KMT2ATDP1ALDH1A1KDM4E | |
| SCHEMBL14671420 | 0.75 | KDM4E (0.61) | MEN1KMT2ATDP1ALDH1A1KDM4E | |
| Bicarbonate SCHEMBL5782303 | 0.73 | KMT2A (0.52) | MEN1KMT2ATDP1ALDH1A1KDM4E | |
| Bicarbonate SCHEMBL5782296 | 0.73 | KMT2A (0.52) | MEN1KMT2ATDP1ALDH1A1KDM4E | |
| SCHEMBL31163550 | 0.73 | HDAC6 (0.55) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562017-A1 | NOVEL ACC INHIBITORS | Pfizer Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20240109915-A1 | NOVEL ACC INHIBITORS | PFIZER INC. (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024023727-A1 | NOVEL ACC INHIBITORS | PFIZER INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109915-A1 | NOVEL ACC INHIBITORS | CBR3, NAT1, ACACB | MEN1 4404/4885KMT2A 3997/4885TDP1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.